title: Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials.
abstract: In rodent models, undercarboxylated osteocalcin (ucOC) acts as a hormone that promotes insulin sensitivity and secretion. If ucOC plays a similar role in humans, then antiresorptive therapies, which reduce ucOC levels, may increase the risk of insulin resistance and diabetes. We tested whether antiresorptive therapies result in higher fasting glucose, increased weight, or greater diabetes incidence in post hoc analyses of three randomized, placebo-controlled trials in postmenopausal women: Fracture Intervention Trial (FIT) (N = 6151) of alendronate (4 years), Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial (HORIZON-PFT) (N = 7113) of zoledronic acid (3 years), and Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial (N = 7076) of denosumab (3 years). Fasting glucose was measured annually in FIT and HORIZON in a subset of women, and every 6 months in FREEDOM in all participants. Weight was measured annually in all trials. Incident diabetes was identified from adverse event reports, initiation of diabetes medication, or elevated fasting glucose. Differences in fasting glucose changes from randomization to trial conclusion between treatment and placebo groups were not statistically significant: -0.47 mg/dL in FIT, 0.20 mg/dL in HORIZON-PFT, and 0.09 mg/dL in FREEDOM, all p > 0.6. Weight change differed between treatment and placebo groups in FIT (0.32 kg, p = 0.003) and FREEDOM (0.31 kg, p = 0.023) but not in HORIZON-PFT (0.15 kg, p = 0.132). In the three trials combined, diabetes occurred in 203 and 225 women assigned to treatment or placebo, respectively. Diabetes incidence was not increased in any of the treatment groups or in the pooled estimate (pooled relative risk [RR] = 0.90; 95% confidence interval [CI] 0.74-1.10). Antiresorptive therapy does not have a clinically important effect on fasting glucose, weight, or diabetes risk in postmenopausal women. Contrary to predictions from mouse models, reduced bone turnover does not appear to play a significant role in glucose metabolism in humans.
authors: University of California San Francisco, San Francisco, CA, USA. aschwartz@psg.ucsf.edu
authors: Ann V
authors: AV
authors: Schwartz
authors: Anne L
authors: AL
authors: Schafer
authors: Andrew
authors: A
authors: Grey
authors: Eric
authors: E
authors: Vittinghoff
authors: Lisa
authors: L
authors: Palermo
authors: Li-Yung L
authors: LY
authors: Lui
authors: Robert B
authors: RB
authors: Wallace
authors: Steven R
authors: SR
authors: Cummings
authors: Dennis M
authors: DM
authors: Black
authors: Douglas C
authors: DC
authors: Bauer
authors: Ian R
authors: IR
authors: Reid
mesh_terms: D000368:Aged; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000097:blood / Q000139:chemically induced; D004195:Disease Models, Animal; D005215:Fasting / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D007333:Insulin Resistance; D051379:Mice; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000188:drug therapy* / Q000453:epidemiology; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D050071:Bone Density Conservation Agents